Dr. John O'Horo | sciencenewsnet.in

Breaking News

New York State, City and Bronx Borough Officials Celebrate the 125th Anniversary of the Bronx Zoo

Silent flight edges closer to take off, according to new research

Novel material supercharges innovation in electrostatic energy storage

A Common Pathway in the Brain That Enables Addictive Drugs to Hijack Natural Reward Processing Has Been Identified by Mount Sinai

MSU expert to attend oral arguments in SCOTUS case that could turn homelessness into a crime

New urine-based test detects high-grade prostate cancer, helping men avoid unnecessary biopsies

Dana-Farber Chief Scientific Officer, Kevin Haigis, PhD, elected as Fellow of the American Association for the Advancement of Science

Hubble Goes Hunting for Small Main Belt Asteroids

Two U Professors Selected as AAAS Fellows

New research finds electric vehicles depreciate faster than gas cars, but the trend is changing

19 Apr, 2024

Mayo Clinic research shows bebtelovimab to be a reliable option for treating COVID-19 in era of BA.2, other subvariants

August 15, 2022 sarah JonasResearch Results

Mayo Clinic researchers say the monoclonal antibody bebtelovimab, already authorized by the Food and Drug Administration for emergency use on the omicron variant of COVID-19, is a reliable option to treat BA.2 and other COVID-19 subvariants. The findings of their multisite, retrospective study involving 3,607 high-risk patients appear in the Journal of Infectious Diseases.